Better proteins. Fewer experiments. Faster to product.
Scientists design new proteins, optimize each property in parallel, and learn from every data point. All on Cradle.
From first design
to final protein
From first design
to final protein
Initial hits to optimized candidates: With Cradle, each round leverages your experimental data to make the next one better.
Initial hits to optimized candidates: With Cradle, each round leverages your experimental data to make the next one better.
Design new proteins.
Design new proteins.
Start with a target, or your own sequence. Cradle designs an optimized plate from data and the scientist’s domain knowledge.
Start with a target, or your own sequence. Cradle designs an optimized plate from data and the scientist’s domain knowledge.
Optimize every property.
Optimize every property.
Compress your time to target protein by improving efficacy, developability, and manufacturability in parallel.
Compress your time to target protein by improving efficacy, developability, and manufacturability in parallel.
Learn from each experiment.
Learn from each experiment.
Round two knows what round one learned—so results compound from your experimental data.
Round two knows what round one learned—so results compound from your experimental data.
If you can assay it, you can engineer it on Cradle.
Medicines, crops, materials. Peptides, enzymes, vaccines, antibodies. Uniquely, Cradle works on all of them—whether the protein exists already or not.
Medicines, crops, materials. Peptides, enzymes, vaccines, antibodies. Uniquely, Cradle works on all of them—whether the protein exists already or not.
“In vitro, or it didn't happen.”
We test models with real data from our own lab—street smart, not just book smart.
We’re an AI company with a pipetting habit, and we share our learnings—workflows, benchmarks, even failures—to help move the field forward.
Our mission is to enable every scientist to turn today's impossible cures, foods, and materials into tomorrow's ordinary.
Let’s empower
every scientist.
Design, optimization, and learning in a single workflow, scaled across all your teams and programs.
Design, optimization, and learning in a single workflow, scaled across all your teams and programs.
Experimental Scientists
Experimental Scientists
Point-and-click candidate design and optimization—ML capabilities in the hands of a bench scientist.
Point-and-click candidate design and optimization—ML capabilities in the hands of a bench scientist.
Computational Scientists
Computational Scientists
Everything in the web application is in the API. Script it, scale it, wire it into your stack to scale your workflow.
Everything in the web application is in the API. Script it, scale it, wire it into your stack to scale your workflow.
R&D Leadership
R&D Leadership
Every experiment your teams have ever run on any campaign, leveraged for a compounding advantage.
Every experiment your teams have ever run on any campaign, leveraged for a compounding advantage.
Enterprise-grade security
Cradle is a protein engineering platform that is both ISO27001 and SOC2 Type II certified. Our platform runs on Google Cloud infrastructure, with strong technical controls, data isolation, and continuous monitoring. Customer data is always securely held and accessible only to those the customer authorizes.
Enterprise-grade security
Cradle is a protein engineering platform that is both ISO27001 and SOC2 Type II certified. Our platform runs on Google Cloud infrastructure, with strong technical controls, data isolation, and continuous monitoring. Customer data is always securely held and accessible only to those the customer authorizes.
Enterprise-grade security
Cradle is a protein engineering platform that is both ISO27001 and SOC2 Type II certified. Our platform runs on Google Cloud infrastructure, with strong technical controls, data isolation, and continuous monitoring. Customer data is always securely held and accessible only to those the customer authorizes.
Tried, applied, and loved by industry leaders
Tried, applied, and loved by industry leaders
Therapeutic peptide: ≥50% hit rate on four tight constraints
Three late-stage programs at a top-20 pharma company had stalled after many rounds. One Cradle round per program met all limits for potency, specificity, expression and thermostability. This was 5× faster than the partner's estimate.
VHH: <2 nM binding to three snake venom toxins
An academic team needed one antivenom binder that works without cold storage. In two rounds, the best VHH also reached a Tm of 76.7 °C and 1.59× expression.
Enzyme: +20 °C thermostability with higher activity
In two rounds, Cradle scientists raised the Tm of a haloalkane dehalogenase to 65 °C. Activity went up 1.29× and expression went up 2.06×.
IgG: 10 potent, developable candidates in three rounds
Prior screening and in-house optimization at a top-50 pharma company did not give a usable candidate. Cradle learned from that failed data and met the potency target plus six developability criteria. All 10 candidates moved to the next pipeline stage.
5× faster
Therapeutic peptides
High thermostability
Sub-nanomolar binding
Haloalkane dehalogenase
1.29× activity
Developability
IgG
Tried, applied, and loved by industry leaders
Tried, applied, and loved by industry leaders
Therapeutic peptide: ≥50% hit rate on four tight constraints
Three late-stage programs at a top-20 pharma company had stalled after many rounds. One Cradle round per program met all limits for potency, specificity, expression and thermostability. This was 5× faster than the partner's estimate.
5× faster
Therapeutic peptides
5× faster
Therapeutic peptides
VHH: <2 nM binding to three snake venom toxins
An academic team needed one antivenom binder that works without cold storage. In two rounds, the best VHH also reached a Tm of 76.7 °C and 1.59× expression.
High thermostability
Sub-nanomolar binding
High thermostability
Sub-nanomolar binding
Enzyme: +20 °C thermostability with higher activity
In two rounds, Cradle scientists raised the Tm of a haloalkane dehalogenase to 65 °C. Activity went up 1.29× and expression went up 2.06×.
1.29× activity
1.29× activity
IgG: 10 potent, developable candidates in three rounds
Prior screening and in-house optimization at a top-50 pharma company did not give a usable candidate. Cradle learned from that failed data and met the potency target plus six developability criteria. All 10 candidates moved to the next pipeline stage.
Developability
IgG
Developability
IgG
“Through our partnership with Cradle, we are embedding advanced AI directly into how we innovate, enabling our teams to shorten development time and bring real-world biosolutions faster to market.”
Claus Fuglsang Crone
Chief Scientific Officer, Novonesis
“Cradle's platform provides us with a scalable, scientist-centric solution to maximize the opportunities in our biologics portfolio and potentially deliver faster, more effective medicines to patients.”
Anastasia Hager, Ph.D.
Global Head of Drug Discovery Sciences, Bayer
“Cradle's AI-based protein design platform provides easy access and acceleration to protein optimization for the discovery pipeline.”
Eswar Narayanan
Director, Corteva Catalyst
“Through our partnership with Cradle, we are embedding advanced AI directly into how we innovate, enabling our teams to shorten development time and bring real-world biosolutions faster to market.”
Claus Fuglsang Crone
Chief Scientific Officer, Novonesis
“Cradle's platform provides us with a scalable, scientist-centric solution to maximize the opportunities in our biologics portfolio and potentially deliver faster, more effective medicines to patients.”
Anastasia Hager, Ph.D.
Global Head of Drug Discovery Sciences, Bayer
“Cradle's AI-based protein design platform provides easy access and acceleration to protein optimization for the discovery pipeline.”
Eswar Narayanan
Director, Corteva Catalyst
“Through our partnership with Cradle, we are embedding advanced AI directly into how we innovate, enabling our teams to shorten development time and bring real-world biosolutions faster to market.”
Claus Fuglsang Crone
Chief Scientific Officer, Novonesis
“Cradle's platform provides us with a scalable, scientist-centric solution to maximize the opportunities in our biologics portfolio and potentially deliver faster, more effective medicines to patients.”
Anastasia Hager, Ph.D.
Global Head of Drug Discovery Sciences, Bayer
“Cradle's AI-based protein design platform provides easy access and acceleration to protein optimization for the discovery pipeline.”
Eswar Narayanan
Director, Corteva Catalyst
The partnership shouldn’t be.
With Cradle,
No royalties, no milestones. Buy a license, keep your data. We’re here to help scientists and we like to keep things simple.
Follow Cradle
Sign up for our newsletter
Built with ❤️ in Amsterdam & Zurich
Follow Cradle
Sign up for our newsletter
Built with ❤️ in Amsterdam & Zurich
Follow Cradle
Sign up for our newsletter